Articles

Videos

Podcasts

Clinical

Long-term extension trial results show a consistent safety profile and durable efficacy for the treatment of adults with the skin condition.

Bristol Myers Squibb Reports Positive Data on Deucravacitinib for Plaque Psoriasis

Delafloxacin (Baxdela) is a fluoroquinolone antibacterial indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia caused by designated susceptible bacteria.

Daily Medication Pearl: Delafloxacin (Baxdela)

With Epsolay treatment, inflammatory lesions of rosacea were reduced by nearly 70% by the end of both 12-week trials compared with a 38% to 46% reduction with the vehicle cream.



FDA Approves Benzoyl Peroxide Cream for Treatment of Inflammatory Lesions of Rosacea

Ruxolitinib (Opzelura) is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis.

Daily Medication Pearl: Ruxolitinib (Opzelura)

On this week's episode, Suzy is joined by Michelle Henry, MD, from Skin & Aesthetic Surgery of Manhattan, a board-certified dermatologist located in New York.

Pharmacist Moms: Coffee With Suzy - Episode 13

Among individuals taking the medication with standard-of-care topical corticosteroids, approximately 41% achieved clear or almost clear skin at 16 weeks.

Clinical Trial Results Show Lilly’s Lebrikizumab Improves Severity of Atopic Dermatitis

The phase 3, multicenter, randomized, double-blinded, comparative clinical study was evaluating the efficacy and safety of ABP 654 compared with ustekinumab in adult patients with moderate to severe plaque psoriasis.

Biosimilar Candidate to Ustekinumab Shows Positive Results Treating Plaque Psoriasis

Abrocitinib (Cibinqo) is a Janus kinase inhibitor indicated for the treatment of adults with refractory moderate-to-severe atopic dermatitis.

Daily Medication Pearl: Abrocitinib (Cibinqo)

Aftersun Aloe Vera naturally soothes sunburns, minor skin irritations, and abrasions.

Daily OTC Pearl: Aftersun Aloe Vera

Regeneron’s supplemental biologics license application for the drug targets patients aged 12 years and older.

FDA Accepts Dupixent for Priority Review for Eosinophilic Esophagitis

® Dermatology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of skin disorders, including psoriasis, atopic dermatitis, eczema, and acne.